Christine Terré

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Sylvie Castaigné, Cécile Pautas, Christine Terré et al. · The Lancet · 2012 · 975 citations

Hematological Malignancy, Oncology, Gemtuzumab Ozogamicin +8

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

Éric Jourdan, Nicolas Boissel, Sylvie Chevret et al. · Blood · 2013 · 350 citations

Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Juliette Lambert, Cécile Pautas, Christine Terré et al. · Haematologica · 2018 · 336 citations · Full text

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With<i>NPM1</i>Mutation: A Study by the Acute Leukemia French Association Group

Marie Balsat, Aline Renneville, Xavier Thomas et al. · Journal of Clinical Oncology · 2017 · 288 citations

Hematological Malignancy, Residual Disease, Transplantation +15

Myeloid cell differentiation arrest by miR-125b-1 in myelodysplasic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation

Marina Bousquet, Cathy Quelen, Roberto Rosati et al. · The Journal of Experimental Medicine · 2008 · 248 citations · Full text